Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing’s disease

OBJECTIVE: This study evaluated short- and long-term efficacy and safety of the second-generation somatostatin receptor ligand pasireotide alone or in combination with dopamine agonist cabergoline in patients with Cushing’s disease (CD). STUDY DESIGN: This is an open-label, multicenter, non-comparat...

Descripción completa

Detalles Bibliográficos
Autores principales: Feelders, Richard A., Fleseriu, Maria, Kadioglu, Pinar, Bex, Marie, González-Devia, Deyanira, Boguszewski, Cesar Luiz, Yavuz, Dilek Gogas, Patino, Heather, Pedroncelli, Alberto M., Maamari, Ricardo, Chattopadhyay, Arghya, Biller, Beverly M. K., Pivonello, Rosario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10593462/
https://www.ncbi.nlm.nih.gov/pubmed/37876540
http://dx.doi.org/10.3389/fendo.2023.1165681

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10593462/
https://www.ncbi.nlm.nih.gov/pubmed/37876540
http://dx.doi.org/10.3389/fendo.2023.1165681

Ejemplares similares